The UK pharmaceutical market. An overview

PharmacoEconomics

Volumn 10, Issue SUPPL. 2, 1996, Pages 14-25

  Towse, Adrian ^a  

^a Office of Health Economics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DRUG COST; DRUG MARKETING; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0029798750     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199600102-00005     Document Type: Conference Paper

References (33)

1. Laing W. Managing the NHS: past present and agenda for the future. Office of Health Economics, 1994
2. 9th Compendium of Health Statistics, Office of Health Economics, 1995
3. Audit Commission. Briefing on GP fundholding. HMSO, 1995
4. Department of Health. Memoranda. In: Health Committee Second Report, priority setting in the NHS: The NHS drugs budget, Vol. II, minutes of evidence and appendices. House of Commons Session 1993-94; HMSO, 1994
5. Griffin J. Government measures and UK prescribing habits. Scrip 1995; Nov: 12-14
6. Hale D, Towse A. Value of the pharmaceutical industry to the UK economy. Office of Health Economics, 1995
7. NHS Executive. Prescribing expenditure: guidance on allocations and budget setting for 1995-6. Executive Letter (95) 8: 1995
8. Wilson RPH, Buchan I, Walley T. Alterations in prescribing by general practitioner landholders: an observational study. BMJ 1995; 311: 1347-50
9. Whynes DK, Baines DL, Tolley KH. GP fundholding and the costs of prescribing. J Pubic Health Med 1995; 17 (3): 323-9
10. Medicines cheaper over the counter. Drug Ther Bull 1995; 33 (6 Suppl.)
11. Proprietary Association of Great Britain. OTC Directory 1995/96. Pharmacists' Association of Great Britain, 1995
12. Hughes D, McGuire A. Patient charges and the utilisation of NHS prescription medicines: some estimates using a cointegration procedure. Health Econ 1995; 4: 213-20
13. Association of the British Pharmaceutical Industry (ABPI). A guide to the Pharmaceutical Price Regulation Scheme (PPRS). ABPI, 1994
14. Scherer FM. US industrial policy and the pharmaceutical industry. In: Towse A, editor. Industrial policy and the pharmaceutical industry. Office of Health Economics, 1995
15. Health Committee. Priority setting in the NHS: the NHS drugs budget, Vol. I, report. House of Commons Session 1993-94; HMSO, 1994
16. Freemantle N, Henry D, Maynard A, et al. Promoting cost effective prescribing. BMJ 1995; 310: 955-6
17. Department of Health. Government response to the Second Report from the Health Committee. House of Commons Session 1993-94; HMSO, 1994
18. Walley T. A UK national prescribing list? PharmacoEconomics 1995; 7 (6): 471-4
19. Towse A, Wells N. Cost effectiveness studies may not be cost effective [letter]. BMJ 1995; 126: 311
20. General Medical Services Committee (GMSC), Discussion document on 'A national formulary linked to a prescription charge policy and unified funding of prescribing'. GMSC, 1995
21. Audit Commission. A prescription for improvement: towards more rational prescribing in general prectice. HMSO, 1994
22. Yarrow G. CEC and EC member state industrial policy and the pharmaceutical industry. In: Towse A, editor. Industrial policy and the pharmaceutical industry. Office of Health Economics, 1995
23. NHS Executive. Purchasing high-tech health care for patients at home. Executive Letter (95) 5: 1995
24. NHS Executive. Purchasing and prescribing. Executive Letter (94) 72: 1994
25. Crump BJ, Panton R, Drummond MF, et al. Transferring the costs of expensive treatments from secondary to primary care. BMJ 1995; 310: 509-12
26. NHS Executive. NHS prescribing of new products for multiple sclerosis. Executive Letter (95) 97: 1995
27. NHS Executive. Commercial approaches to the NHS regarding disease management packages. Executive Letter (94) 94: 1994
28. Holmes J, Dunning J. Factors influencing the location of multinational investment in the pharmaceutical industry. In: Towse A, editor. Industrial policy and the pharmaceutical industry. Office of Health Economics, 1995
29. Association of the British Pharmaceutical Industry (ABPI). The competitiveness of the UK-based pharmaceutical industry. ABPI, 1995
30. Department of Health. Virginia Bottomley welcomes pioneering guidelines for the economic evaluation of medicines. Press release 94/251, 1994
31. The Labour Party. Renewing the NHS. Labour's agenda for a healthier Britain. 1995
32. Hoffmeyer UK, McCarthy TR. Financing health care. Dordrecht: Kluwer Academic Publishers, 1994
33. Towse A. An overview of the NERA study and its proposals for health care reform. In: Towse A, editor. Financing health care in the the UK: a discussion of NERA's prototype model to replace the NHS. Office of Health Economics, 1995